Osimertinib-Savolitinib Combination Treats Lung Cancer
The Phase 3 SAFFRON trial shows improved survival outcomes for patients with specific MET-driven lung cancer.
Updated on Oct. 25, 2026 in Cancer
Results from the phase 3 SAFFRON trial demonstrate that combining osimertinib and savolitinib significantly improves progression-free and overall survival for patients with EGFR-mutated non-small cell lung cancer. This treatment combination is designed for patients whose disease progressed on prior osimertinib treatment due to MET amplification or overexpression.
Why it matters
The study offers a new standard of care for patients facing advanced lung cancer that has developed resistance to traditional osimertinib therapy. By targeting MET-driven progression, the combination provides a more effective alternative than standard platinum/pemetrexed chemotherapy.
In the trial of 338 patients, the combination therapy achieved a median progression-free survival of 7.6 months compared to 5.4 months for chemotherapy. The regimen, consisting of 80 mg daily osimertinib and 300 mg twice-daily savolitinib, also demonstrated a 32% reduction in death risk.
The players
ESMO Congress
This is an international annual meeting for oncology professionals that serves as a platform for presenting landmark cancer research and clinical trial data.
FDA
This federal agency is responsible for protecting public health by regulating human and veterinary drugs, biological products, and medical devices.
The details
The SAFFRON trial randomized patients 1:1 to receive either the combination therapy or standard chemotherapy. Participants included individuals across 25 countries who had EGFR-mutated advanced non-small cell lung cancer.
Timeline
July 6, 2026: Data cutoff date for the SAFFRON trial analysis.
August 2026: Topline results showed the study met primary endpoints.
September 2026: New drug application submitted to the FDA.
October 23-27, 2026: Results presented at the 2026 ESMO Congress.
Health Landscape
The SAFFRON trial sets a new clinical standard for managing cancer resistance, representing a significant shift in addressing EGFR-mutated non-small cell lung cancer. This approach validates the use of combination therapies to overcome MET-driven progression, moving beyond the limitations of single-agent treatments.
Patients who have previously exhausted osimertinib options may now have access to an effective secondary treatment pathway. This development provides oncologists with a new standard of care to extend progression-free survival for those with specific genetic markers.
The takeaway
Patients experiencing disease progression on osimertinib should consult with their oncology teams regarding genetic testing for MET amplification. This targeted combination therapy highlights the importance of matching specific cancer mutations with the appropriate pharmacological intervention.
Further reading
Learn more about the latest research in the field at Cancer.
